Screener
Bristol-Myers Squibb BMY Divestiture and other proceeds
Divestiture and other proceeds at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept bmy:DivestitureAndOtherProceeds.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
FAQ
- What is Bristol-Myers Squibb's divestiture and other proceeds?
- Bristol-Myers Squibb (BMY) reported divestiture and other proceeds of $209M in Q2 2026.
- How has Bristol-Myers Squibb's divestiture and other proceeds changed year-over-year?
- Bristol-Myers Squibb's divestiture and other proceeds decreased by 22.6% year-over-year, from $270M to $209M.
- What is the long-term trend for Bristol-Myers Squibb's divestiture and other proceeds?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's divestiture and other proceeds has grown at a 13.7% compound annual growth rate (CAGR), from $748M to $1.1B.
- What does divestiture and other proceeds mean?
- Captures cash inflows from the sale of business units, assets, or other non-core investments. This metric highlights the impact of portfolio optimization and strategic restructuring on the company's cash position.
Ask your AI about Bristol-Myers Squibb's divestiture and other proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude